Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)